Clinical TrialsSearch results for "cytarabine"
Number of results: 39
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12
Completed
- HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumab
- Patients with high-risk advanced hematological disease
- Kanda Yoshinobu
- 2019-03-12